Status:
UNKNOWN
Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease
Lead Sponsor:
TC Erciyes University
Conditions:
Temporomandibular Joint Disorders
Temporomandibular Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
It will be evaluate the safety of mesenchymal stem cells and adipose tissue derived stromal vascular fraction (SVF) in temporomandibular joint disease cases.
Detailed Description
umbilical cord derived mesenchymal stem cells produced under GMP facility in Erciyes University and SVF produced in operation theatre.
Eligibility Criteria
Inclusion
- Chronic temporomandibular arthritic disorder
- History of pain and joint noises for at least 3 months
- Must have more than VAS 5 TMJ pain
- must have internal derangement of TMJ
- Limited mouth opening
- Magnetic resonance imaging evidence of effusion or degeneration
- Already treated with conservative methods (occlusal splint,pharmacological and/or physio-kinesio therapy) without satisfactory benefit.
Exclusion
- Cancer patients
- Immunosupressed patients
- Previous TMJ traumas and fractures
- Previous TMJ surgeries
- TMJ ankylosis
Key Trial Info
Start Date :
October 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05305833
Start Date
October 1 2021
End Date
December 1 2023
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erciyes University
Kayseri, Turkey (Türkiye), 38039